Prostatic Neoplasms Clinical Trials in New York, New York

7 studies are recruiting for prostatic neoplasms in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

   Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Icahn School of Medicine at Mount Sinai ( Site 0009), New York, New York

   Locations

   298 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06925737 on ClinicalTrials.gov

2. Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

   The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mount Sinai Doctors Urology Faculty Practice, New York, New York

   Locations

   34 in total

   Run by

   Clarity Pharmaceuticals Ltd

   See if you can join NCT06056830 on ClinicalTrials.gov

3. A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

   The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of the combination of JNJ-87189401 and JNJ-78278343 is, with or …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York, New York

   Locations

   19 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06095089 on ClinicalTrials.gov

4. A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

   The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the RP2CD of JNJ-7827834 and JNJ-95298177 with or without JNJ-87189401 is for…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Columbia University Medical Center, New York, New York

   Locations

   6 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07082920 on ClinicalTrials.gov

5. A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

   The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with advanced prostate cancer in Part 2 (…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Columbia University Medical Center, New York, New York

   Locations

   5 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07319871 on ClinicalTrials.gov

6. Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

   To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Weill Cornell Medicine - New York - Presbyterian Hospital, New York, New York

   Locations

   21 in total

   Run by

   Blue Earth Therapeutics Ltd

   See if you can join NCT05413850 on ClinicalTrials.gov

7. Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

   This investigator-initiated, prospective study evaluates the diagnostic utility of rhPSMA-7.3 (¹⁸F) PET/CT (flotufolastat F18, marketed as POSLUMA®) in men with biopsy-proven, low-risk or favorable intermediate-risk prostate cancer managed with active surveillance. The study aims to determine wheth…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mount Sinai Hospital / Icahn School of Medicine at Mount Sinai, New York, New York

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT07285057 on ClinicalTrials.gov